The effect of royal jelly supplementation on hormonal status,insulin resistance and inflammatory factors in patients with polycystic ovary syndrome

The effect of royal jelly supplementation on hormonal status, insulin resistance and inflammatory factors in patients with polycystic ovary syndrome: pilot study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190212042686N3

Enrollment

Registered

2022-12-28

Start date

2022-12-05

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: will receive Royal jelly capsule (1000 mg) once a day manufactured by STP pharma factory for 2 months. Intervention 2: Control group: The placebo capsule filled wit

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Female volunteers aged 15-45 with clinical symptoms of hyperandrogenism

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Having diseases such as autoimmune diseases Digestive diseases Liver disease Thyroid Unstable cardiovascular diseases Severe respiratory disease (Asthma and Chronic bronchitis) Taking any type of vitamin and mineral supplements in the last six months People with a history of allergies

Design outcomes

Primary

Measure	Time frame
Estrogen. Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Testosterone. Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Sex Hormone-Binding Globulin (SHBG). Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Fasting blood sugar. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Insulin resistance with HOMA-IR score. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Interleukin 6. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Hs-CRP. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Body mass scale. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Weight scale and stadiometer.	—

Measure

Time frame

Estrogen. Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Testosterone. Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Sex Hormone-Binding Globulin (SHBG). Timepoint: Baseline and 2 months after the treatment. Method of measurement: ELISA Test.;Fasting blood sugar. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Insulin resistance with HOMA-IR score. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Interleukin 6. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Hs-CRP. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Electrochemiluminescence Test.;Body mass scale. Timepoint: Baseline and 2 months after the treatment. Method of measurement: Weight scale and stadiometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr.Majid Mobasseri

Tabriz University of Medical Sciences

Mobasserim@tbzmed.ac.ir+98 41 3334 8939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026